Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 2...
February 16 2018 - 7:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its
fourth quarter and full-year 2017 financial results on Thursday,
February 22, 2018 before market opens. Management will conduct a
conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST)
that day to discuss the financial results and to provide a business
update.
Dial-in InformationU.S. Dial-in
Number: (888) 645-5785International Dial-in Number:
(970) 300-1531Conference ID: 3395518
Replay InformationU.S. Dial-in
Number: (855) 859-2056Replay International Dial-in
Number: (404) 537-3406Conference ID: 3395518
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online in
the investor relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company that is applying a unique approach to gene science based on
Nobel Prize-winning technology to discover and develop precise
medicines for patients with serious, chronic conditions. Through
its Genome5000™ program, Lexicon scientists have studied the role
and function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s growth and
future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon’s ability to meet its capital
requirements, successfully commercialize XERMELO (telotristat
ethyl), successfully conduct preclinical and clinical development
and obtain necessary regulatory approvals of sotagliflozin, LX2761,
LX9211 and its other potential drug candidates on its anticipated
timelines, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon’s actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
“Risk Factors” in Lexicon’s annual report on Form 10-K for the year
ended December 31, 2016, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of
new information, future events or otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzSenior Director, Corporate
Communications and AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024